NTRBWHIGH SIGNALFINANCIAL10-K

NTRBW shows severe financial deterioration with operating losses doubling to $10.3M despite a significant cash infusion, indicating accelerated cash burn.

The company's operating losses more than doubled while R&D expenses increased 59%, suggesting intensified development activities that are burning through cash at an alarming rate. Despite raising substantial capital (cash increased 775% to $4.3M), the dramatic increase in losses indicates this funding may be insufficient to sustain operations at current burn rates.

Comparing 2025-04-28 vs 2024-05-01View on EDGAR →
FINANCIAL ANALYSIS

NTRBW experienced severe financial deterioration with operating losses doubling from $4.9M to $10.3M and net losses increasing 91% to $10.5M, while R&D expenses surged 59% to $3.1M. The company appears to have raised significant capital as cash jumped 775% to $4.3M, but operating cash flow worsened by 31% to negative $4.6M. This combination of dramatically higher losses, increased spending, and worsening cash flow despite a capital raise signals unsustainable burn rates that could quickly deplete the new funding.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+814.6%
$8K→$76K

Interest expense surged 814.6% — significant debt increase or rising rates materially impacting earnings.

Cash & Equivalents
Balance Sheet
+774.7%
$493K→$4.3M

Cash position surged 774.7% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+369.2%
$1.0M→$4.8M

Current assets grew 369.2% — improving short-term liquidity or inventory/receivables build.

Operating Income
P&L
-111.1%
-$4.9M→-$10.3M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
-91.1%
-$5.5M→-$10.5M

Net income declined 91.1% — review whether driven by operations, interest costs, or non-recurring items.

Capital Expenditure
Cash Flow
+77.8%
$52K→$92K

Capital expenditure jumped 77.8% — major investment cycle underway; assess returns on deployment.

R&D Expense
P&L
+59.1%
$2.0M→$3.1M

R&D investment increased 59.1% — signals commitment to future product development, though near-term margin impact.

Accounts Receivable
Balance Sheet
-50.3%
$149K→$74K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Operating Cash Flow
Cash Flow
-31.2%
-$3.5M→-$4.6M

Operating cash flow fell 31.2% — earnings quality concerns; investigate working capital changes and non-cash items.

Inventory
Balance Sheet
+25.8%
$169K→$212K

Inventory built 25.8% — monitor whether demand supports this build or if write-downs may follow.

LANGUAGE CHANGES
NEW — 2025-04-28
PRIOR — 2024-05-01
ADDED
As of April 25, 2025, the registrant had 11,154,171 shares of common stock outstanding.
Recent Developments On February 13, 2025, we signed an addendum to the Commercial Development and Clinical Supply Agreement for our lead product, Aversa Fentanyl, being developed with our partner, Kindeva Drug Delivery, a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products.
Nutriband and Kindeva have revised their agreement to formalize their exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments.
The development work being conducted under this agreement supports the development of Nutriband s AVERSA abuse-deterrent technology in general, which can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants.
Laboratory studies to be performed consist of in vitro manipulation and chemical extraction studies per FDA guidance.
+7 more — sign up free →
REMOVED
As of April 30, 2024, the registrant had 10,969,870 shares of common stock outstanding.
Preclinical studies to be performed consist of laboratory-based in vitro manipulation and chemical extraction studies per FDA guidance.
The purchase price of $2,250,000, consisting of 62,500 shares of common stock, valued at $1,850,000, and cash of $400,000, and are to pay Mr.
The royalty is payable pursuant to the acquisition agreement and continues as long as we generate revenue from our utilization or sale of the abuse deterrent intellectual property we acquired as part of the acquisition of 4P Therapeutics.
We believe that AVERSA Fentanyl, once approved by the US FDA will significantly deter the abuse and accidental misuse of fentanyl transdermal patches.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →